肾脏去神经术2026:试验证据、指南推荐与临床实践实施策略
综述总结肾脏去神经术(RDN)治疗高血压的试验证据与指南推荐,指出假手术对照随机试验显示RDN在未控制或抵抗性高血压患者中安全且可临床意义地降低血压,主要国际指南推荐其作为辅助治疗,但报销不足限制推广。
要点
- 假手术对照试验证实RDN在未控制或抵抗性高血压中安全且降压有临床意义。
- 主要国际指南推荐RDN作为其他手段失败或血压控制不足时的辅助治疗。
- 患者选择与偏好应纳入共享决策,手术应在有经验的中心进行。
核心结论
- RDN已确立为高血压管理的辅助治疗手段,主要在药物治疗基础上联合使用。
- RDN在慢性肾脏病、房颤、心衰等交感驱动增强疾病中的潜在用途正在探索。
研究设计与样本
- 综述总结了假手术对照随机临床试验、观察性研究及主要国际指南推荐。
主要发现
- 一系列假手术对照随机试验在未控制或抵抗性高血压患者中(联用或不联用降压药)显示RDN操作安全且血压降低有临床意义。
- 观察性研究显示RDN降压疗效持久性可达10年。
- RDN在慢性肾脏病、房颤、心衰患者中结果最有希望。
关键数值与推荐
- 主要国际指南推荐RDN作为未控制或抵抗性高血压患者在其他手段失败或血压控制不足时的辅助治疗。
临床怎么用
- 患者选择与患者偏好应纳入共享决策过程。
- RDN手术应在有经验的中心进行。
- 临床医生应将器械治疗作为改善血压管理的额外选项,主要与药物治疗联合。
局限性
- 美国已批准RDN,但欧洲、亚太及许多其他地区目前缺乏充分报销,是广泛临床实施的障碍。
- 操作方面需进一步优化以减少手术时间并增强降压疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Renal nerves are critical modulators of kidney function and blood pressure (BP) control. Their influence on sodium and fluid retention, renin release and vasoconstriction rendered them a therapeutic target more than a century ago when surgical splanchnicectomy emerged as one of the first effective antihypertensive therapies. Revisiting the concept using catheter-based approaches to ablate renal afferent and efferent nerves more selectively with various energy sources demonstrated the efficacy of renal denervation in reducing sympathetic nerve activity. A series of sham-controlled randomised clinical trials in patients with uncontrolled or resistant hypertension either on or off concomitant antihypertensive drugs demonstrated procedural safety and clinically meaningful BP reduction. Durability of the BP lowering efficacy has been demonstrated out to 10 years in observational studies. Major international guidelines now recommend renal denervation as an adjunct therapy in patients with uncontrolled or resistant hypertension where other means have failed or resulted in insufficient BP control. Patient selection and patient preference are relevant aspects to be considered in a shared decision-making process leading up to the denervation procedure, which should be performed in experienced centres. While approved in the USA, most countries in Europe, Asia-Pacific and many other regions lack adequate reimbursement currently, which remains a barrier for more widespread implementation into clinical practice despite favourable cost-effectiveness analyses. While now established in the context of hypertension management, ongoing research explores its potential utility in other conditions characterised by increased sympathetic drive, with most promising results in patients with chronic kidney disease, atrial fibrillation, heart failure and others. Further refinement of procedural aspects may reduce procedure time and augment the BP lowering efficacy. Clinicians should embrace the additional options that device-based therapies offer to improve BP management, mostly in combination with pharmacologic therapies. After all, it is just another means of bringing the pressure down.
引用
- Sesa-Ashton, Woodhams, Herat, et al. Renal denervation in 2026: trial evidence, guideline recommendations and implementation strategies for clinical practice. Heart. 2026. PMID: 41819559. doi:10.1136/heartjnl-2025-326186
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。